Amprion
SAN FRANCISCO, CA · Biotechnology · 50 employees
Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing. Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson’s disease (PD), Lewy body dementia (LBD/
Funding history
- Seed — $5.0M — Jul 2026
- Venture - Series Unknown — $5.8M — Sep 2024
- Seed — $3.8M — Sep 2024
- Venture - Series Unknown — $11.0M — Jul 2022
Recent signals
- Jul 08, 2026: Raised $5.0M in Seed
- Sep 27, 2024: Raised $5.8M in Venture - Series Unknown
- Sep 25, 2024: Raised $3.8M in Seed
- Jul 15, 2022: Raised $11.0M in Venture - Series Unknown
See plans & pricing → Track Amprion’s funding, hiring, and signals — with verified contacts — on Fundz.